Takashi Muramatsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Takashi Muramatsu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Hisako Muramatsu
Aichi Gakuin University
3 shared publications - Chen Lan
Department of Biochemistry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
2 shared publications - Keiko Ichihara-Tanaka
Department of Health and Nutrition, Faculty of Psychological and Physical Science, Aichi Gakuin University, 12 Araike, Iwasaki-cho, Nisshin, Aichi 470-0195, Japan
2 shared publications - Chizuru Hirose
Chuden CTI Ltd, Higashisakura 1st Bld., 1-3-10 Higashisakura, Higashi-ku, Nagoya 461-0005, Japan
1 shared publication Hisako Muramatsu
Department of Biochemistry and Division of Disease Models, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
1 shared publication- Katsunori Yokoi
Department of Biochemistry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
1 shared publication
Latest Publications
- 11 August 2012
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 16 (10) , 999-1011
Basigin: a multifunctional membrane protein with an emerging role in infections by malaria parasites
(2012). Basigin: a multifunctional membrane protein with an emerging role in infections by malaria parasites. Expert Opinion on Therapeutic Targets: Vol. 16, No. 10, pp. 999-1011. doi: 10.1517/14728222.2012.711818
- 11 August 2012
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 16 (10) , 999-1011
Basigin: a multifunctional membrane protein with an emerging role in infections by malaria parasites
(2012). Basigin: a multifunctional membrane protein with an emerging role in infections by malaria parasites. Expert Opinion on Therapeutic Targets: Vol. 16, No. 10, pp. 999-1011. doi: 10.1517/14728222.2012.711818
- Open Access
- 1 February 2011
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 17 (5) , 410-423
Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Midkine (MK) is a heparin-binding cytokine, and promotes growth, survival, migration and other activities of target cells. After describing the general properties of MK, this review focuses on MK and MK inhibitors as therapeutics for diseases in the central nervous system. MK is strongly expressed during embryogenesis especially at the midgestation period, but is expressed only at restricted sites in adults. MK expression is induced upon tissue injury such as ischemic brain damage. Since exogenously administered MK or the gene transfer of MK suppresses neuronal cell death in experimental systems, MK has the potential to treat cerebral infarction. MK might become important also in the treatment of neurodegenerative diseases such as Alzheimer's disease. MK is involved in inflammatory diseases by enhancing migration of leukocytes, inducing chemokine production and suppressing regulatory T cells. Since an aptamer to MK suppresses experimental autoimmune encephalitis, MK inhibitors are promising for the treatment of multiple sclerosis. MK is overexpressed in most malignant tumors including glioblastoma, and is involved in tumor invasion. MK inhibitors may be of value in the treatment of glioblastoma. Furthermore, an oncolytic adenovirus, whose replication is under the control of the MK promoter, inhibits the growth of glioblastoma xenografts. MK inhibitors under development include antibodies, aptamers, glycosaminoglycans, peptides and low molecular weight compounds. siRNA and antisense oligoDNA have proved effective against malignant tumors and inflammatory diseases in experimental systems. Practical information concerning the development of MK and MK inhibitors as therapeutics is described in the final part of the review.
- 1 February 2011
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 17 (5) , 410-423
Open AccessMidkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Midkine (MK) is a heparin-binding cytokine, and promotes growth, survival, migration and other activities of target cells. After describing the general properties of MK, this review focuses on MK and MK inhibitors as therapeutics for diseases in the central nervous system. MK is strongly expressed during embryogenesis especially at the midgestation period, but is expressed only at restricted sites in adults. MK expression is induced upon tissue injury such as ischemic brain damage. Since exogenously administered MK or the gene transfer of MK suppresses neuronal cell death in experimental systems, MK has the potential to treat cerebral infarction. MK might become important also in the treatment of neurodegenerative diseases such as Alzheimer's disease. MK is involved in inflammatory diseases by enhancing migration of leukocytes, inducing chemokine production and suppressing regulatory T cells. Since an aptamer to MK suppresses experimental autoimmune encephalitis, MK inhibitors are promising for the treatment of multiple sclerosis. MK is overexpressed in most malignant tumors including glioblastoma, and is involved in tumor invasion. MK inhibitors may be of value in the treatment of glioblastoma. Furthermore, an oncolytic adenovirus, whose replication is under the control of the MK promoter, inhibits the growth of glioblastoma xenografts. MK inhibitors under development include antibodies, aptamers, glycosaminoglycans, peptides and low molecular weight compounds. siRNA and antisense oligoDNA have proved effective against malignant tumors and inflammatory diseases in experimental systems. Practical information concerning the development of MK and MK inhibitors as therapeutics is described in the final part of the review.
- Open Access
- 1 January 2011
- Published by Springer Nature in International Archives of Medicine
- Vol. 4 (1) , 1
Midkine as a factor to counteract the deposition of amyloid beta-peptide plaques: in vitro analysis and examination in knockout mice
Midkine is a heparin-binding cytokine involved in cell survival and various inflammatory processes. Midkine accumulates in senile plaques of patients with Alzheimer's disease, while it counteracts the cytotoxic effects of amyloid β-peptide and inhibits its oligomerization. The present study was conducted to understand the role of midkine upon plaque formation of amyloid β-peptide.
- 1 January 2011
- Published by Springer Nature in International Archives of Medicine
- Vol. 4 (1) , 1
Open AccessMidkine as a factor to counteract the deposition of amyloid beta-peptide plaques: in vitro analysis and examination in knockout mice
Midkine is a heparin-binding cytokine involved in cell survival and various inflammatory processes. Midkine accumulates in senile plaques of patients with Alzheimer's disease, while it counteracts the cytotoxic effects of amyloid β-peptide and inhibits its oligomerization. The present study was conducted to understand the role of midkine upon plaque formation of amyloid β-peptide.
- Open Access
- 1 January 2010
- Published by Springer Nature in International Archives of Medicine
- Vol. 3 (1) , 12
Midkine inhibitors: application of a simple assay procedure to screening of inhibitory compounds
Midkine is a heparin-binding cytokine and is involved in etiology of various diseases. Thus, midkine inhibitors are expected to be helpful in treatment of many diseases.
- 1 January 2010
- Published by Springer Nature in International Archives of Medicine
- Vol. 3 (1) , 12
Open AccessMidkine inhibitors: application of a simple assay procedure to screening of inhibitory compounds
Midkine is a heparin-binding cytokine and is involved in etiology of various diseases. Thus, midkine inhibitors are expected to be helpful in treatment of many diseases.
- Open Access
- 1 January 2010
- Published by Japan Academy in Proceedings of the Japan Academy, Series B
- Vol. 86 (4) , 410-425
Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases
Midkine is a heparin-binding cytokine or a growth factor with a molecular weight of 13 kDa. Midkine binds to oversulfated structures in heparan sulfate and chondroitin sulfate. The midkine receptor is a molecular complex containing proteoglycans. Midkine promotes migration, survival and other activities of target cells. Midkine has about 50% sequence identity with pleiotrophin. Mice deficient in both factors exhibit severe abnormalities including female infertility. In adults, midkine is expressed in damaged tissues and involved in the reparative process. It is also involved in inflammatory reactions by promoting the migration of leukocytes, induction of chemokines and suppression of regulatory T cells. Midkine is expressed in a variety of malignant tumors and promotes their growth and invasion. Midkine appears to be helpful for the treatment of injuries in the heart, brain, spinal cord and retina. Midkine inhibitors are expected to be effective in the treatment of malignancies, rheumatoid arthritis, multiple sclerosis, renal diseases, restenosis, hypertension and adhesion after surgery. (Communicated by Takao SEKIYA, M.J.A.)
- 1 January 2010
- Published by Japan Academy in Proceedings of the Japan Academy, Series B
- Vol. 86 (4) , 410-425
Open AccessMidkine, a heparin-binding cytokine with multiple roles in development, repair and diseases
Midkine is a heparin-binding cytokine or a growth factor with a molecular weight of 13 kDa. Midkine binds to oversulfated structures in heparan sulfate and chondroitin sulfate. The midkine receptor is a molecular complex containing proteoglycans. Midkine promotes migration, survival and other activities of target cells. Midkine has about 50% sequence identity with pleiotrophin. Mice deficient in both factors exhibit severe abnormalities including female infertility. In adults, midkine is expressed in damaged tissues and involved in the reparative process. It is also involved in inflammatory reactions by promoting the migration of leukocytes, induction of chemokines and suppression of regulatory T cells. Midkine is expressed in a variety of malignant tumors and promotes their growth and invasion. Midkine appears to be helpful for the treatment of injuries in the heart, brain, spinal cord and retina. Midkine inhibitors are expected to be effective in the treatment of malignancies, rheumatoid arthritis, multiple sclerosis, renal diseases, restenosis, hypertension and adhesion after surgery. (Communicated by Takao SEKIYA, M.J.A.)
- 8 August 2008
- Published by Wiley in Proteomics
- Vol. 8 (16) , 3350-3359
Glycosaminoglycan‐binding cytokines as tumor markers
A significant proportion of cytokines bind to glycosaminoglycans such as heparin. Glycosaminoglycans are involved in signaling, stabilization and/or storage of these cytokines. Typical examples of glycosaminoglycan‐binding cytokines are basic fibroblast growth factor (bFGF), interleukin‐8 (IL‐8), monocyte chemoattractant protein‐1 (MCP‐1), vascular endothelial growth factor (VEGF), VEGF‐C, hepatocyte growth factor (HGF), granulocyte colony‐stimulating factor (G‐CSF), midkine, and pleiotrophin. All are present in the tumor microenvironment and promote tumor growth, tumor invasion and/or tumor angiogenesis. Serum or plasma levels of glycosaminoglycan‐binding cytokines are frequently elevated in patients with various malignant tumors. High levels of these cytokines are usually correlated with the occurrence of metastasis and a poor prognosis. The mode of elevation of individual glycosaminoglycan‐binding cytokines in patients with malignant tumors is summarized here. Further studies, especially with multiple cytokines, are expected to make assays clinically useful for both early detection and prognostic prediction.
- 8 August 2008
- Published by Wiley in Proteomics
- Vol. 8 (16) , 3350-3359
Glycosaminoglycan‐binding cytokines as tumor markers
A significant proportion of cytokines bind to glycosaminoglycans such as heparin. Glycosaminoglycans are involved in signaling, stabilization and/or storage of these cytokines. Typical examples of glycosaminoglycan‐binding cytokines are basic fibroblast growth factor (bFGF), interleukin‐8 (IL‐8), monocyte chemoattractant protein‐1 (MCP‐1), vascular endothelial growth factor (VEGF), VEGF‐C, hepatocyte growth factor (HGF), granulocyte colony‐stimulating factor (G‐CSF), midkine, and pleiotrophin. All are present in the tumor microenvironment and promote tumor growth, tumor invasion and/or tumor angiogenesis. Serum or plasma levels of glycosaminoglycan‐binding cytokines are frequently elevated in patients with various malignant tumors. High levels of these cytokines are usually correlated with the occurrence of metastasis and a poor prognosis. The mode of elevation of individual glycosaminoglycan‐binding cytokines in patients with malignant tumors is summarized here. Further studies, especially with multiple cytokines, are expected to make assays clinically useful for both early detection and prognostic prediction.